指南与共识呼吸危重症与机械通气呼吸道感染肺栓塞与肺血管病

RAND适宜性小组评估英国ARDS管理指南在COVID-19大流行中的适用性

RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic.
指南 / 共识 · Thorax · 2021-05-27

该研究采用RAND适宜性方法,由11名重症监护专家组成的专家组,以英国近期ARDS管理指南为模板,对COVID-19相关及非COVID-19相关ARDS的管理选项进行适宜性评分。专家组认为不应偏离现有指南推荐的循证支持策略,仅在诊断性支气管镜的适宜性上存在显著分歧,并建议对COVID-19相关ARDS常规使用皮质类固醇及基于高静脉血栓栓塞怀疑降低全量抗凝阈值。

要点

  • COVID-19相关ARDS的支持性管理应与非COVID-19 ARDS相同,遵循现有指南。
  • 仅在确诊或疑似COVID-19患者行诊断性支气管镜的适宜性上存在显著专家分歧。
  • 对COVID-19相关ARDS,专家组推荐常规皮质类固醇治疗并降低全量抗凝阈值。

核心结论

  • 专家组认为没有理由偏离近期指南中概述的ARDS循证支持策略。

研究设计与样本

  • 由11名重症监护从业者组成的专家组,采用RAND适宜性方法,以英国近期ARDS指南为模板进行评分。
  • 评分采用1-9分制(1-3不适宜,4-6不确定,7-9适宜),评估住院不同时间点及不同SARS-CoV-2感染状态或严重程度下的ARDS管理选项。
  • 修改后的在线调查包含76个问题,细分为检查(16)、无创呼吸支持(18)、ARDS基本ICU管理(20)、难治性低氧血症管理(8)、药物治疗(7)和抗凝(7)。

主要发现

  • 专家间的分歧仅在评估确诊或疑似COVID-19患者行诊断性支气管镜的适宜性时具有显著性。
  • 专家对最终调查的回应表明,无论是否诊断COVID-19,ARDS的支持性管理应相同。
  • 对于COVID-19相关ARDS患者,专家组推荐常规使用皮质类固醇治疗,并基于对静脉血栓栓塞性疾病的高怀疑指数降低全量抗凝的阈值。

关键数值与推荐

  • 评分量表:1-3为不适宜,4-6为不确定,7-9为适宜。
  • 调查问卷共76个问题,分为检查(16)、无创呼吸支持(18)、基本ICU管理(20)、难治性低氧血症管理(8)、药物治疗(7)和抗凝(7)。

临床怎么用

  • 临床应遵循现有已发表的ARDS管理指南中的相关循证干预措施。
  • 对COVID-19相关ARDS患者,可考虑常规皮质类固醇治疗,并基于高静脉血栓栓塞怀疑降低全量抗凝阈值。
  • 对确诊或疑似COVID-19患者行诊断性支气管镜需谨慎,因专家意见存在显著分歧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 has become the most common cause of acute respiratory distress syndrome (ARDS) worldwide. Features of the pathophysiology and clinical presentation partially distinguish it from 'classical' ARDS. A Research and Development (RAND) analysis gauged the opinion of an expert panel about the management of ARDS with and without COVID-19 as the precipitating cause, using recent UK guidelines as a template. METHODS: An 11-person panel comprising intensive care practitioners rated the appropriateness of ARDS management options at different times during hospital admission, in the presence or absence of, or varying severity of SARS-CoV-2 infection on a scale of 1-9 (where 1-3 is inappropriate, 4-6 is uncertain and 7-9 is appropriate). A summary of the anonymised results was discussed at an online meeting moderated by an expert in RAND methodology. The modified online survey comprising 76 questions, subdivided into investigations (16), non-invasive respiratory support (18), basic intensive care unit management of ARDS (20), management of refractory hypoxaemia (8), pharmacotherapy (7) and anticoagulation (7), was completed again. RESULTS: Disagreement between experts was significant only when addressing the appropriateness of diagnostic bronchoscopy in patients with confirmed or suspected COVID-19. Adherence to existing published guidelines for the management of ARDS for relevant evidence-based interventions was recommended. Responses of the experts to the final survey suggested that the supportive management of ARDS should be the same, regardless of a COVID-19 diagnosis. For patients with ARDS with COVID-19, the panel recommended routine treatment with corticosteroids and a lower threshold for full anticoagulation based on a high index of suspicion for venous thromboembolic disease. CONCLUSION: The expert panel found no reason to deviate from the evidence-based supportive strategies for managing ARDS outlined in recent guidelines.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Griffiths M, Meade S, Summers C, et al. RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic. Thorax. 2021. PMID: 34045363. doi:10.1136/thoraxjnl-2021-216904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。